TCGA-75-7030-01A-11R-1949-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- TGF_BETA_SIGNALING+0.560
- HEDGEHOG_SIGNALING+0.550
- TNFA_SIGNALING_VIA_NFKB+0.500
- UV_RESPONSE_DN+0.500
- ANGIOGENESIS+0.470
- COAGULATION+0.460
- KRAS_SIGNALING_UP+0.450
- APICAL_JUNCTION+0.420
- APICAL_SURFACE+0.420
Top 10 suppressed
- E2F_TARGETS-0.750
- MYC_TARGETS_V2-0.720
- MYC_TARGETS_V1-0.690
- G2M_CHECKPOINT-0.640
- OXIDATIVE_PHOSPHORYLATION-0.580
- MTORC1_SIGNALING-0.490
- DNA_REPAIR-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- PI3K_AKT_MTOR_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ULC1729T_S65 | — | cohortSQ1 | 0.961 |
| 2 | TCGA-CR-7393-01A-11R-2016-07 | — | — | 0.955 |
| 3 | TCGA-OL-A6VQ-01A-12R-A41B-07 | — | A | 0.945 |
| 4 | TCGA-56-A4ZJ-01A-11R-A262-07 | — | cohortSQ1 | 0.944 |
| 5 | cdb7b56c-ddca-4596-bfa2-6823c12837e2 | — | — | 0.944 |
| 6 | TCGA-A2-A0ES-01A-11R-A115-07 | — | A | 0.944 |
| 7 | SRR12475153 | — | — | 0.939 |
| 8 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.939 |
| 9 | SRR35579845 | — | A | 0.938 |
| 10 | 4c7083b3-eccc-4d80-a31d-6fd3cd0222b4 | — | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.560 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.550 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.450 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.420 | Temsirolimus | — uncovered |
| HYPOXIA | 0.380 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |